Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects and safety of efgartigimod given intravenously in adults with primary immune thrombocytopenia ITP, a condition where the immune system attacks platelets. This phase 3 clinical trial aims to determine how well efgartigimod controls platelet counts compared to a placebo during a 24-week double-blinded treatment period. The study is sponsored by argenx and includes follow-up periods to monitor ongoing effects and safety. Participants will be randomly assigned in a 21 ratio to receive either efgartigimod IV or placebo IV during the double-blinded treatment period. After this, all participants will receive efgartigimod IV during a first 52-week open-label treatment phase, followed by an optional second 52-week open-label phase. After completing these treatment periods, participants will have an approximately 8-week follow-up while off the study drug, with total study participation lasting up to 138 weeks. During the study, participants will have regular blood tests to measure platelet counts and assess disease control. Researchers will track the number of weeks participants maintain platelet counts above specified levels and monitor any bleeding events or adverse effects. Safety is closely observed throughout the trial, including antibody responses to the drug. Participants will have scheduled visits and assessments throughout treatment and follow-up to gather comprehensive data on efgartigimods impact.
Actively Recruiting
Neovascular age-related macular degeneration nAMD, often called wet AMD, involves abnormal growth of new blood vessels in the retina, the light-sensitive tissue at the back of the eye. This research aims to evaluate the safety and effectiveness of Surabgene Lomparvovec, an investigational gene therapy, in adults aged 50 and older who have been previously treated for nAMD. Approximately 561 participants will be enrolled globally and randomized into three groups to compare different treatments. Participants will be assigned to one of three groups two groups receive a single subretinal injection of Surabgene Lomparvovec at different doses, and the third group receives Ranibizumab injections as needed throughout the study. Ranibizumab is given as an intravitreal injection into the jelly-like tissue inside the eye, while Surabgene Lomparvovec is delivered beneath the retina. The studys assessment period begins two weeks before randomization and follows participants for up to five years. During the study, participants will attend monthly visits at a hospital or clinic where medical assessments, blood tests, side effect monitoring, and questionnaires will be conducted to evaluate treatment effects. Researchers will track the annual rate of anti-VEGF injections and monitor adverse events over five years, along with changes in visual acuity. The study is designed to assess long-term treatment burden, safety, and preservation of vision in a real-world context.